AlphAIAlphAI — Financial news for AI agents
BenzingaOCT 33 min read$ANGO

AngioDynamics Eyes Growth Despite Tariffs - AngioDynamics (NASDAQ:ANGO)

AngioDynamics, Inc. ( NASDAQ:ANGO ) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.

Original reporting
Benzinga · Triveni Kothapalli
Published Oct 3, 2025, 4:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 3, 2025, 5:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics Eyes Growth Despite Tariffs - AngioDynamics (NASDAQ:ANGO) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$ANGOBullishMed
01

Why it matters

The company's ability to outperform despite tariffs suggests operational resilience and potential for sustained growth.

02

Market read

The positive earnings report enhances investor confidence in AngioDynamics and the Med-Tech sector.

03

What to watch

Possible slowdown in hospital procurement cycles or regulatory delays affecting Med-Tech sales.

Timing: Immediate to short-term (next 1-3 months)

Background

AngioDynamics reported better-than-expected earnings, driven by growth in its Med-Tech segment, despite ongoing tariffs affecting imports.

Company-level read

Ticker impact

$ANGOBullishHigh confidence
Context

Primary focus of the news is AngioDynamics (NASDAQ:ANGO), which posted strong quarterly results and raised FY2026 guidance.

Expected impact

Moderate upward movement in the near term (1-3 months).

Evidence & confidence

Strong quarterly results and upward guidance suggest solid operational performance, supported by positive market sentiment.

Market effects

Sector

Positive outlook for Med-Tech sector due to strong earnings and guidance

Regional

Limited regional impact; primarily US-focused

Global

Moderate, as Med-Tech is a global industry but news is US-centric

Counterpoint

What could challenge this read

Potential overestimation of growth; tariffs and supply chain issues could dampen future performance.

Key entities

  • Company
    AngioDynamics

    A provider of minimally invasive medical devices and therapies.

Read at source← All news

Related articles

AUG 11
$ANGOMed

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.

yahoo.com4 min
JUL 21
$ANGOMed

AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.

yahoo.com7 min
SEP 20
$JAZZHighAI 8/10

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals (JAZZ) raised its revenue estimate for Ziihera to $3B-$5B, citing potential expansion in multiple cancer types. The company expects Ziihera to become a first-line standard of care for HER2-positive gastroesophageal adenocarcinoma. Jazz also announced pipeline expansions in epilepsy and sleep-wake disorders, including new clinical trials and formulations.

finance.yahoo.com2 min
SEP 20
$LFMDMed

LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?

LifeMD (LFMD) partnered with AT&T to offer free virtual-health memberships to 29 million eligible customers in 11 states, with a nationwide expansion planned for 2027. The $19 monthly fee is waived, but services like visits and prescriptions remain payable. LifeMD aims to convert access into recurring demand for paid care, potentially reducing acquisition costs and benefiting from repeat consultations. The phased rollout allows for measuring enrollment and utilization before expansion.

yahoo.com2 min